In a press release today, MAIA Biotechnology, Inc. (NYSE American: MAIA) shared encouraging results from its Phase 2 clinical trial, THIO-101. The trial assessed the combination of ateganosine (THIO) with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who had not responded to at least two standard therapy regimens. The study showed positive efficacy data, indicating potential benefits for this patient population. MAIA is a clinical-stage biopharmaceutical company dedicated to developing targeted immunotherapies for cancer.